To the Editor, We have read with great interest the recent article by Rollin and collaborators (1) concerning the use of glargine and NPH insulin in children (0-8 years old) with type 1 diabetes mellitus (T1DM). We would like to comment on the context which it emerges from, on aspects about the study design, and on how data is presented and interpreted. We believe that taking our comments into account would substantially change the interpretation drawn from this study.
treatment. The patients were followed monthly during the first 3 months, and then on a every 3-month basis. The only period in which the follow-up of patients under the NPH insulin and the glargine treatments were comparable was the first 3-month period.
To assess the glycemic control achieved by the two drugs the Authors compared HbA 1c values from before starting glargine with values achieved along the oneyear glargine treatment.
It is difficult to understand why the Authors used the mean baseline HbA 1c (8.68%) plus the end of the 3-month NPH treatment HbA 1c (the so called "NPH -3 and 0" [8.44%]) (1), instead of using the on-study-NPH-HbA 1c values (not directly provided by the Authors) to assess the treatment effect of NPH insulin. On the other hand, the effects of glargine were evaluated using only the on-study-glargine-HbA 1c values. We calculated HbA 1c at the end of the 3-month NPH treatment (8.20%) and redesigned the "table 1" provided the article (1) ( Table 1) .
Despite all the methodological limitations pointed out for the study of Rollin and collaborators (1), the fact that each individual was used as their own control and that a short period of time elapsed between the two treatments (NPH insulin and glargine) makes it possible to draw some conclusions about the comparison of the two treatments.
In order to compare one must take into account the bias imputed to the data and, of course, use data from treatments of same length for each therapy ( Figure 1 ). Using this approach, despite all the contrary bias, NPH insulin provided a better glycemic control of diabetes at the end of the 3-month period when compared to glargine in the same period (HbA 1c of 8.20% vs. 8.94%, p = 0.02 -for NPH insulin vs. glargine, respectively). At the end of the three months, the difference in HbA 1c between the two treatment regimens was of -0.74% (CI95%: -0.11% to -1.37%, p = 0.02), in favor of NPH insulin − Table 1 and Figure 1 ). As in the efficacy analysis, safety analysis is extremely bias-limited and some epidemiologic-behavioral phenomena need to be acknowledged in this regard.
The comparison of hypoglycemic episodes occurs in two different follow-up periods: 1) intensive NPH insulin period, when patients were adjusting their insulin dosages; 2) glargine period (following the intensive NPH insulin period), when patient hypoglycemia profile, resistance to insulin and insulin requirements were also known by family and physicians. This can explain the differences between NPH insulin and glargine, regarding hypoglycemic episodes. Furthermore, as mentioned above, the period of time in which patients were using glargine was four times greater than the length of NPH insulin therapy. In this setting, education gains and a possible dilution of hypoglycemic episodes may have occurred. It would be interesting to know what were the insulin doses and hypoglycemic rates during the three months for both treatment regimens, since in this period patients had the same time to adjust to the new treatment, and were submitted to the same followup regimen.
Arq Bras Endocrinol Metab. 2010;54/1 Glargine is not superior to NPH insulin in children Another important aspect related to the safety profile of glargine is the recent report of a possible association between its use and higher cancer incidence (7, 8) . Until this issue is clarified and appropriate long-term safety data on this analog is available, it does not seem worthwhile to use glargine in patients who will need continuous treatment for life.
According to the discussion above we can conclude that the study conducted by Rollin and collaborators presents methodological limitations that preclude the conclusions reached by the Authors. Moreover, glargine and NPH insulin were adequately compared in a recent randomized and controlled trial, which demonstrated that both have the same efficacy in lowering HbA 1c , and display similar rates of hypoglycemic episodes (3) . Not failing to remember the Hyppocratic Oath taken: "primum non nocere", instead of glargine, NPH insulin (a drug that is very similar in efficacy and has long-term safety data available) seems to be a more reasonable, first-line approach for children with T1DM.
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